

January 28, 2019

To Listing Department, NATIONAL STOCK EXCHANGE OF INDIA LIMITED Exchange Plaza, Bandra Kurla Complex, Bandra (E), MUMBAI -400 051 Company Code No. AUROPHARMA	To The Corporate Relations Department BSE LIMITED Phiroz Jeejeebhoy Towers, 25 th floor, Dalal Street, MUMBAI -400 001 Company Code No. 524804
--	--

Dear Sirs,

Sub: Clarification on news item appeared in "www.economictimes.com" on January 27, 2019 captioned "Aurobindo recalls nearly 5 lakh bottles of blood pressure drug in US."

Ref : BSE Letter No. L/SURV/ONL/RV/SS/ (2018-2019)/ 179 dated January 28, 2019
NSE Letter No. NSE/CM/Surveillancel 7871 dated January 28, 2019

This has reference to your above cited letters seeking clarification on the subject matter.

In this regard, we would like to inform you that our US subsidiary, Aurobindo Pharma USA Inc., has initiated a voluntary recall of 80 lots (nearly 5 lakh bottles) of Amlodipine Valsartan Tablets USP, Valsartan HCTZ Tablets, USP and Valsartan Tablets USP on 31st Dec 2018, and the value of the aforesaid products is not material. Hence, we have not intimated it earlier to stock exchanges.

Please take the information on record.

Thanking you,

Yours faithfully,
For AUROBINDO PHARMA LIMITED


B. Adi Reddy
Company Secretary

